MARKET

CHRS

CHRS

Coherus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.20
+0.77
+4.18%
Closed 16:08 11/13 EST
OPEN
18.39
PREV CLOSE
18.43
HIGH
19.40
LOW
18.28
VOLUME
1.31M
TURNOVER
--
52 WEEK HIGH
23.91
52 WEEK LOW
8.32
MARKET CAP
1.35B
P/E (TTM)
-99.9479
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CHRS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CHRS News

  • Edited Transcript of CHRS earnings conference call or presentation 6-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.1d ago
  • Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences
  • GlobeNewswire.1d ago
  • The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
  • Zacks.1d ago
  • Coherus BioSciences Announces New Employment Inducement Grants
  • GlobeNewswire.5d ago

More

Industry

Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.16%

Hot Stocks

Name
Price
%Change

About CHRS

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
More

Webull offers Coherus Biosciences Inc (CHRS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.